Navigation Links
Erectile Dysfunction Drugs Market to Sink to USD 3.4 Billion by 2019: Transparency Market Research
Date:9/24/2014

Albany, New York (PRWEB) September 24, 2014

The global erectile dysfunction drugs market was worth $4.3 billion in 2012. It is expected to decline at an aggregate rate of 4.5% between 2013 and 2019, which means the market will be valued at $3.4 billion in 2019.

All facts and figures have be provided through a research report titled “Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, published by Transparency Market Research.

To browse through the research report, or to view the ToC, please visit: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

The report showed that Viagra (sildenafil citrate) by Pfizer held 45% of the global erectile dysfunction drugs market in 2012. Its majority hold over the market is predicted to decline after patent exclusivity rights expire in 2013 in Europe and other countries. Cialis (tadalafil) held the second-largest market share with $1.9 billion in 2012. Its patent exclusivity will reportedly expire in 2017, supplementing the decline of the erectile dysfunction drugs market by 2019. The same is to be expected from Levitra/Staxyn (Vardenafil) by Bayer, whose patent exclusivity is set to expire in 2018. The report explains that once the patents expire, the market will be flooded with competitive generic drugs with similar chemical compositions, reducing the revenue generated by the major players in the market.

Factors that might improve the growth of the erectile dysfunction drugs market are the approval of the new promising drugs Zydena (udenafil) and Stendra/Spedra (avanafil) in mid 2014.

The report categorized the global erectile dysfunction market according to the product brands or pipeline analysis. By products, the report investigates Viagra, Cialis, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva. By pipeline analysis, the report identifies Vitaros, Uprima, Gene therapy, Melanocortin Activators, and Topiglan.

For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

By geography, the research report identifies the regions of North America, Europe, Asia-Pacific, and Rest of the World. The North American region dominated the global erectile dysfunction drug market in revenue created. It is expected to maintain its dominance throughout the forecast period.

The key players explained in the report are Pfizer, GlaxoSmithKline, Bayer, Dong-A Pharmaceutical Corporation Limited, Eli Lilly And Company, Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus Incorporated, S.K. Chemicals Corporation Limited, Meda Pharmaceuticals, and Apricus Biosciences, Incorporated.

Erectile dysfunction is a male inability to generate and/or maintain penile erection, for the sake of a fully successful sexual intercourse. It primarily affects men above the age of 40. Typical causes of erectile dysfunction are diabetes and hypertension, along with a host of common habits attributed to a sedentary lifestyle, obesity, excessive consumption of alcohol, smoking, use of recreational drugs, and use of anti-depressants.

Contact:

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com
Web: http://www.transparencymarketresearch.com/

Read the full story at http://www.prweb.com/releases/2014/09/prweb12196007.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Does cycling increase risk for erectile dysfunction, infertility, or prostate cancer?
2. All men with gout should be routinely screened for erectile dysfunction
3. Erectile dysfunction can be reversed without medication
4. What is the link between erectile dysfunction and heart disease?
5. Erectile Dysfunction Tied to Long-Term Narcotic Use in Men
6. Long-term use of prescription painkillers for back pain linked to erectile dysfunction in men
7. Most Men With Erectile Dysfunction Dont Seem to Get Treatment
8. Most men with erectile dysfunction remain untreated, say US scientists
9. Erectile Dysfunction Clinic Set to Open April 1st in Maryland
10. Common erectile dysfunction drug not helpful for heart failure patients, study finds
11. The Elator Announces it's Recognition from The Sinclair Institute for its Penile Support Device for Men Suffering from Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
Breaking Medicine Technology: